Gabriel Maciel1, Cynthia S Crowson2, Eric L Matteson2, Divi Cornec3. 1. Mayo Clinic College of Medicine, Rochester, Minnesota, and Hospital Maciel, Montevideo, Uruguay. 2. Mayo Clinic College of Medicine, Rochester, Minnesota. 3. Mayo Clinic College of Medicine, Rochester, Minnesota, and Brest Teaching Hospital, Brest, France.
Abstract
OBJECTIVE: To report the point prevalence of primary Sjögren's syndrome (SS) in the first US population-based study. METHODS: Cases of all potential primary SS patients living in Olmsted County, Minnesota, on January 1, 2015, were retrieved using Rochester Epidemiology Project resources, and ascertained by manual medical records review. Primary SS cases were defined according to physician diagnosis. The use of diagnostic tests was assessed and the performance of classification criteria was evaluated. The number of prevalent cases in 2015 was also projected based on 1976-2005 incidence data from the same source population. RESULTS: A total of 106 patients with primary SS were included in the study: 86% were female, with a mean ± SD age of 64.6 ± 15.2 years, and a mean ± SD disease duration of 10.5 ± 8.4 years. A majority were anti-SSA positive (75%) and/or anti-SSB positive (58%), but only 22% met American-European Consensus Group or American College of Rheumatology criteria, because the other tests required for disease classification (ocular dryness objective assessment, salivary gland functional or morphologic tests, or salivary gland biopsy) were rarely performed in clinical practice. According to the physician diagnosis, the age- and sex-adjusted prevalence of primary SS was 10.3 per 10,000 inhabitants, but according to classification criteria, this prevalence was only 2.2 per 10,000. The analysis based on previous incidence data projected a similar 2015 prevalence rate of 11.0 per 10,000. CONCLUSION: The prevalence of primary SS in this geographically well-defined population was estimated to be between 2 and 10 per 10,000 inhabitants. Physicians rarely used tests included in the classification criteria to diagnose the disease in this community setting.
OBJECTIVE: To report the point prevalence of primary Sjögren's syndrome (SS) in the first US population-based study. METHODS: Cases of all potential primary SS patients living in Olmsted County, Minnesota, on January 1, 2015, were retrieved using Rochester Epidemiology Project resources, and ascertained by manual medical records review. Primary SS cases were defined according to physician diagnosis. The use of diagnostic tests was assessed and the performance of classification criteria was evaluated. The number of prevalent cases in 2015 was also projected based on 1976-2005 incidence data from the same source population. RESULTS: A total of 106 patients with primary SS were included in the study: 86% were female, with a mean ± SD age of 64.6 ± 15.2 years, and a mean ± SD disease duration of 10.5 ± 8.4 years. A majority were anti-SSA positive (75%) and/or anti-SSB positive (58%), but only 22% met American-European Consensus Group or American College of Rheumatology criteria, because the other tests required for disease classification (ocular dryness objective assessment, salivary gland functional or morphologic tests, or salivary gland biopsy) were rarely performed in clinical practice. According to the physician diagnosis, the age- and sex-adjusted prevalence of primary SS was 10.3 per 10,000 inhabitants, but according to classification criteria, this prevalence was only 2.2 per 10,000. The analysis based on previous incidence data projected a similar 2015 prevalence rate of 11.0 per 10,000. CONCLUSION: The prevalence of primary SS in this geographically well-defined population was estimated to be between 2 and 10 per 10,000 inhabitants. Physicians rarely used tests included in the classification criteria to diagnose the disease in this community setting.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: Y Alamanos; N Tsifetaki; P V Voulgari; A I Venetsanopoulou; C Siozos; A A Drosos Journal: Rheumatology (Oxford) Date: 2005-12-06 Impact factor: 7.580
Authors: S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone Journal: Arthritis Rheum Date: 2008-01
Authors: R Hal Scofield; Rohan Sharma; Nathan Pezant; Jennifer A Kelly; Lida Radfar; David M Lewis; C Erick Kaufman; Sarah Cioli; Judy Harris; Kiely Grundahl; Nelson L Rhodus; Daniel J Wallace; Michael H Weisman; Swamy Venuturupalli; Michael T Brennan; Kristi A Koelsch; Christopher J Lessard; Courtney G Montgomery; Kathy L Sivils; Astrid Rasmussen Journal: Arthritis Care Res (Hoboken) Date: 2020-07-05 Impact factor: 4.794
Authors: Luisa Servioli; Gabriel Maciel; Carlotta Nannini; Cynthia S Crowson; Eric L Matteson; Divi Cornec; Alvise Berti Journal: J Rheumatol Date: 2019-01-15 Impact factor: 4.666
Authors: Peter M Izmirly; Jill P Buyon; Isabella Wan; H Michael Belmont; Sara Sahl; Jane E Salmon; Anca Askanase; Joan M Bathon; Laura Geraldino-Pardilla; Yousaf Ali; Ellen M Ginzler; Chaim Putterman; Caroline Gordon; Charles G Helmick; Hilary Parton Journal: Arthritis Care Res (Hoboken) Date: 2019-05-23 Impact factor: 4.794
Authors: R M Clancy; M C Marion; H C Ainsworth; M J Blaser; M Chang; T D Howard; P M Izmirly; C Lacher; M Masson; K Robins; J P Buyon; C D Langefeld Journal: J Autoimmun Date: 2019-10-31 Impact factor: 7.094
Authors: Yaping Ju; Srikanth Reddy Janga; Wannita Klinngam; J Andrew MacKay; Dillon Hawley; Driss Zoukhri; Maria C Edman; Sarah F Hamm-Alvarez Journal: Exp Eye Res Date: 2018-09-08 Impact factor: 3.467